Pregled bibliografske jedinice broj: 546152
Drug consumption in Croatia: The effects of pricing policy changes
Drug consumption in Croatia: The effects of pricing policy changes // Basic Clin Pharmacol Toxicol 2010 ; 107 (Suppl. 1): 431
Kopenhagen, Danska, 2010. str. 431-431 (poster, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 546152 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Drug consumption in Croatia: The effects of pricing policy changes
Autori
Mađarević, Tomislav ; Buble, Tonći ; Gantumur, Monja ; Vitezić, Miomira ; Šestan, Branko ; Mršić Pelčić, Jasenka ; Vitezić, Dinko
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Basic Clin Pharmacol Toxicol 2010 ; 107 (Suppl. 1): 431
/ - , 2010, 431-431
Skup
WorldPharma2010, 16th IUPHAR WorldCongress of Basis and Clinical Pharmacology
Mjesto i datum
Kopenhagen, Danska, 17.07.2010. - 23.07.2010
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
drug; consumption; cardiovascular drugs; generics; drug prices
Sažetak
The aim of this study is to detect changes in total drug usage and financial expenditure according to legal changes in Croatia, especially considering pricing policy. The data were obtained from the Croatian National Health Insurance Institute for the eight-year period (2001-2008). Financial expenditure data are presented in Euros, while drug utilization data are presented in defined daily doses/1000 inhabitants/day (DDD/1000). During the investigated period drug usage increased 81.33%, while financial expenditure increased 77.23%. ATC C-group (cardiovascular drugs) represents approximately 30% of annual financial expenditure and 50 % of total DDD/1000. While total DDD/1000 increased for approximately 10% every year, financial expenditure increased 10-20% annually until 2006, but since then there have been no significant changes. After the introduction of the new pricing system, at the end of 2005, there was a decrease in price which is calculated in Euro/DDD. This decrease differs from 2-20 % relating to diferent ATC groups, i.e. for C-group is 15.85%. Drugs usage and financial expenditure increased during the investigated period. As a result of the introduction of the new pricing system, which regulates prices of the new original drugs and also stimulates generics prescription, there has been a significant decrease in total financial expenditure.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
062-0620063-0060 - Uporaba kardiovaskularnih lijekova i značaj farmakoekonomskih procjena (Vitezić, Dinko, MZOS ) ( CroRIS)
Ustanove:
Medicinski fakultet, Rijeka
Profili:
Branko Šestan
(autor)
Dinko Vitezić
(autor)
Jasenka Mršić-Pelčić
(autor)
Tomislav Mađarević
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE